Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:estradiol
|
| gptkbp:appliesTo |
gptkb:skin
|
| gptkbp:ATCCode |
G03CA03
|
| gptkbp:contains |
gptkb:estradiol_USP
|
| gptkbp:contraindication |
gptkb:cancer
undiagnosed vaginal bleeding active thromboembolic disorders |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:FDAApproved |
yes
|
| gptkbp:form |
musical composition
|
| gptkbp:frequency |
twice weekly
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vivelle-Dot
|
| gptkbp:indication |
menopausal symptoms
prevention of osteoporosis |
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:pregnancyCategory |
X
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
transdermal
|
| gptkbp:sideEffect |
nausea
headache breast tenderness irritation at application site |
| gptkbp:usedFor |
hormone replacement therapy
|
| gptkbp:bfsParent |
gptkb:estradiol
|
| gptkbp:bfsLayer |
6
|